Therapeutic options in treatment-resistant depression

Abstract The phenomenon of treatment-resistant depression (TRD), described as the occurrence of an inadequate response after an adequate treatment with antidepressant agents (in terms of dose, duration, and adherence), is very common in clinical practice. It has been broadly defined in the context of unipolar major depression, but alternative definitions for bipolar depression have also been suggested. In both cases, there is a remarkable lack of consensus amongst professionals concerning its operative definition. A relatively wide variety of treatment options for unipolar TRD are available, whilst the evidence is very scanty for bipolar TRD. TRD is associated to poor clinical, functional, and social outcomes. Several novel therapeutic options are currently being investigated as promising alternatives, targeting the neurotransmitter system outside of the standard monoamine hypothesis. Augmentation or combination with lithium or atypical antipsychotics appears as a valid option for both conditions, and the same occurs with electroconvulsive therapy. Other non-pharmacological strategies such as deep brain stimulation may be promising alternatives for the future. The use of cognitive behaviour therapy is recommended for unipolar TRD, but there is no evidence supporting its use in bipolar TRD.

[1]  M. Alda,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. , 2013, Bipolar disorders.

[2]  D. Puigdemont,et al.  Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. , 2011, The Journal of clinical psychiatry.

[3]  E. Vieta,et al.  Factors associated with initial treatment response with antidepressants in bipolar disorder , 2011, European Neuropsychopharmacology.

[4]  N. Axmacher,et al.  Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression. , 2011, Journal of psychiatric research.

[5]  M. Berlim,et al.  High frequency repetitive transcranial magnetic stimulation as an augmenting strategy in severe treatment-resistant major depression: a prospective 4-week naturalistic trial. , 2011, Journal of affective disorders.

[6]  M. Trivedi,et al.  Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? , 2010, Journal of affective disorders.

[7]  Takeshi Inoue,et al.  Pramipexole for stage 2 treatment-resistant major depression: An open study , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[8]  A. Cleare,et al.  Discrepancy between subjective and objective severity in treatment-resistant depression: prediction of treatment outcome. , 2010, Journal of psychiatric research.

[9]  P. Fitzgerald,et al.  A randomized trial of unilateral and bilateral prefrontal cortex transcranial magnetic stimulation in treatment-resistant major depression , 2010, Psychological Medicine.

[10]  William W. McDonald,et al.  Accelerated repetitive transcranial magnetic stimulation for treatment‐resistant depression , 2010, Depression and anxiety.

[11]  E. Vieta,et al.  Treatment Options for Bipolar Depression: A Systematic Review of Randomized, Controlled Trials , 2010, Journal of clinical psychopharmacology.

[12]  B. Spivak,et al.  The economic impact of depression: Resistance or severity? , 2010, European Neuropsychopharmacology.

[13]  H. Birnbaum,et al.  Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder , 2010, Current medical research and opinion.

[14]  W. Nolen,et al.  Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine , 2010, Acta psychiatrica Scandinavica.

[15]  A. Serretti,et al.  Identification of clinical factors associated with resistance to antidepressants in bipolar depression: results from an European Multicentre Study , 2010, International clinical psychopharmacology.

[16]  J. Rybakowski,et al.  The utility of Mood Disorder Questionnaire for the detection of bipolar diathesis in treatment-resistant depression. , 2010, Journal of affective disorders.

[17]  D. Luckenbaugh,et al.  A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. , 2010, Archives of general psychiatry.

[18]  M. Frye,et al.  Improving the design of maintenance studies for bipolar disorder , 2010, Current medical research and opinion.

[19]  W. Maier,et al.  Two-Year Outcome of Vagus Nerve Stimulation in Treatment-Resistant Depression , 2010, Journal of clinical psychopharmacology.

[20]  Moon-Soo Lee,et al.  Variables influencing antidepressant medication adherence for treating outpatients with depressive disorders. , 2010, Journal of affective disorders.

[21]  S. Pallanti,et al.  Unilateral low frequency versus sequential bilateral repetitive transcranial magnetic stimulation: is simpler better for treatment of resistant depression? , 2010, Neuroscience.

[22]  J. Calabrese,et al.  Bipolar Depression: Overview and Commentary , 2010, Harvard review of psychiatry.

[23]  E. Callaway,et al.  Deep brain stimulation for obsessive-compulsive disorder and treatment-resistant depression: systematic review , 2010, BMC Research Notes.

[24]  T. Bschor,et al.  No evidence for switching the antidepressant: systematic review and meta‐analysis of RCTs of a common therapeutic strategy , 2010, Acta psychiatrica Scandinavica.

[25]  T. Messer,et al.  Therapieresistente Depressionen , 2009, Fortschritte der Neurologie-Psychiatrie.

[26]  O. Andreassen,et al.  The study protocol of the Norwegian randomized controlled trial of electroconvulsive therapy in treatment resistant depression in bipolar disorder , 2010, BMC psychiatry.

[27]  M. Trivedi,et al.  Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. , 2010, The Journal of clinical psychiatry.

[28]  E. Vieta,et al.  Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis. , 2010, The international journal of neuropsychopharmacology.

[29]  A. Young,et al.  A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). , 2010, The Journal of clinical psychiatry.

[30]  A. Young,et al.  A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). , 2010, The Journal of clinical psychiatry.

[31]  H. Möller,et al.  The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression , 2010, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[32]  P. Girardi,et al.  Treatment‐resistant bipolar depression: towards a new definition , 2009, Acta psychiatrica Scandinavica.

[33]  M. George,et al.  Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression , 2009, Experimental Neurology.

[34]  G. Gao,et al.  Long-term effects of bilateral deep brain stimulation of the subthalamic nucleus on depression in patients with Parkinson's disease. , 2009, Parkinsonism & related disorders.

[35]  A. Nierenberg Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression , 2009, Psychotherapy and Psychosomatics.

[36]  J. Nelson,et al.  Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. , 2009, The American journal of psychiatry.

[37]  R. Emsley,et al.  Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. , 2009, The Journal of clinical psychiatry.

[38]  Tammas Kelly,et al.  The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. , 2009, Journal of affective disorders.

[39]  A. Cleare,et al.  What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. , 2009, Journal of affective disorders.

[40]  R. Shelton,et al.  Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues , 2009, Neuropsychiatric disease and treatment.

[41]  G. Goodwin Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. , 2009, Journal of psychopharmacology.

[42]  A. Cleare,et al.  The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. , 2009, The Journal of clinical psychiatry.

[43]  Arun Ravindran,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. , 2013, Bipolar disorders.

[44]  S. Kaneko,et al.  Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder , 2009, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[45]  M. Fava,et al.  Aripiprazole Augmentation in Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study in Patients with Inadequate Response to Antidepressants , 2009, CNS Spectrums.

[46]  J. O'reardon Introduction and Clinical Presentations , 2009, CNS Spectrums.

[47]  J. O'reardon Pharmacologic and therapeutic strategies in treatment-resistant depression. Introduction and clinical presentations. , 2009, CNS spectrums.

[48]  S. Rauch,et al.  Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression , 2009, Biological Psychiatry.

[49]  M. Krams,et al.  An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder , 2008, Journal of clinical psychopharmacology.

[50]  J. Calabrese,et al.  International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression. , 2008, The Journal of clinical psychiatry.

[51]  B. Spivak,et al.  Serious life events among resistant and non-resistant MDD patients. , 2008, Journal of affective disorders.

[52]  A. Lozano,et al.  Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression , 2008, Biological Psychiatry.

[53]  Eduard Vieta,et al.  Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. , 2008, Journal of affective disorders.

[54]  R. Lam,et al.  Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Metaanalysis , 2008, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[55]  Rusheng Zhang,et al.  Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. , 2008, The Journal of clinical psychiatry.

[56]  E. Vieta,et al.  Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. , 2008, Bipolar disorders.

[57]  P. Fitzgerald,et al.  Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder: A Review , 2008 .

[58]  F. L. Rocha,et al.  Efficacy and safety of antidepressant augmentation with lamotrigine in patients with treatment-resistant depression: a randomized, placebo-controlled, double-blind study. , 2008, Primary care companion to the Journal of clinical psychiatry.

[59]  T. George,et al.  Nicotinic Antagonist Augmentation of Selective Serotonin Reuptake Inhibitor-Refractory Major Depressive Disorder: A Preliminary Study , 2008, Journal of clinical psychopharmacology.

[60]  G. Kirov,et al.  The Effectiveness of Electroconvulsive Therapy in Treatment-Resistant Depression: A Naturalistic Study , 2008, The journal of ECT.

[61]  J. Goldberg Optimizing treatment outcomes in bipolar disorder under ordinary conditions. , 2008, The Journal of clinical psychiatry.

[62]  J. Calabrese,et al.  Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. , 2008, The Journal of clinical psychiatry.

[63]  M. Fava,et al.  The Efficacy and Safety of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder: A Second Multicenter, Randomized, Double-Blind, Placebo-Controlled Study , 2008, Journal of clinical psychopharmacology.

[64]  J. Goldberg What constitutes evidence-based pharmacotherapy for bipolar disorder? Part 2: complex presentations and clinical context. , 2008, The Journal of clinical psychiatry.

[65]  A. Serretti,et al.  The genetics of bipolar disorder: genome ‘hot regions,’ genes, new potential candidates and future directions , 2008, Molecular Psychiatry.

[66]  P. Bech,et al.  Repetitive Transcranial Magnetic Stimulation (rTMS) in Combination with Escitalopram in Patients with Treatment-Resistant Major Depression. A Double-Blind, Randomised, Sham-Controlled Trial , 2008, Pharmacopsychiatry.

[67]  Michael Berk,et al.  The empirical redefinition of the psychometric criteria for remission in bipolar disorder. , 2008, Journal of affective disorders.

[68]  S. Kennedy,et al.  Osmotic-release oral system methylphenidate augmentation of antidepressant monotherapy in major depressive disorder: results of a double-blind, randomized, placebo-controlled trial. , 2008, The Journal of clinical psychiatry.

[69]  E. Vieta,et al.  A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone , 2008, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[70]  R. Gallop,et al.  Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness: A Double-Blind, Placebo-Controlled Study , 2007, Journal of clinical psychopharmacology.

[71]  C. Kosik‐Gonzalez,et al.  Risperidone for Treatment-Refractory Major Depressive Disorder , 2007, Annals of Internal Medicine.

[72]  D. Dudek,et al.  Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. , 2007, Pharmacological reports : PR.

[73]  Mark A Frye,et al.  A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. , 2007, The American journal of psychiatry.

[74]  Julien Mendlewicz,et al.  Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. , 2007, The Journal of clinical psychiatry.

[75]  N. Crossley,et al.  Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. , 2007, The Journal of clinical psychiatry.

[76]  R. Berman,et al.  The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. , 2007, The Journal of clinical psychiatry.

[77]  R. Shelton,et al.  Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. , 2007, The Journal of clinical psychiatry.

[78]  J. Fleck,et al.  Aripiprazole augmentation for treatment-resistant bipolar depression: sustained remission after 36 months. , 2007, Journal of Clinical Psychopharmacology.

[79]  E. Vieta,et al.  [Electroconvulsive therapy in the treatment of bipolar depression]. , 2007, Actas espanolas de psiquiatria.

[80]  T. Suppes,et al.  Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: a failed but clinically useful study , 2007, Acta psychiatrica Scandinavica.

[81]  S. Hollon,et al.  Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. , 2007, The American journal of psychiatry.

[82]  J. Amsterdam,et al.  Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. , 2007, The Journal of clinical psychiatry.

[83]  C. Nemeroff The burden of severe depression: a review of diagnostic challenges and treatment alternatives. , 2007, Journal of psychiatric research.

[84]  J. Krystal,et al.  Preliminary Evidence of Riluzole Efficacy in Antidepressant-Treated Patients with Residual Depressive Symptoms , 2007, Biological Psychiatry.

[85]  M. Thase,et al.  A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. , 2007, The Journal of clinical psychiatry.

[86]  Gustavo Turecki,et al.  Definition, Assessment, and Staging of Treatment—Resistant Refractory Major Depression: A Review of Current Concepts and Methods , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[87]  Klaus P. Ebmeier,et al.  Factors modifying the efficacy of transcranial magnetic stimulation in the treatment of depression: a review. , 2006, The Journal of clinical psychiatry.

[88]  P. Fitzgerald,et al.  A randomized trial of low-frequency right-prefrontal-cortex transcranial magnetic stimulation as augmentation in treatment-resistant major depression. , 2006, The international journal of neuropsychopharmacology.

[89]  J. Calabrese,et al.  Efficacy of Quetiapine Monotherapy in Bipolar I and II Depression: A Double-blind, Placebo-controlled Study (The BOLDER II Study) , 2006, Journal of clinical psychopharmacology.

[90]  S. Kennedy,et al.  Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. , 2006, Bipolar disorders.

[91]  P. Masand,et al.  A Randomized, Double-blind, Placebo-controlled Trial of Augmentation With an Extended Release Formulation of Methylphenidate in Outpatients With Treatment-Resistant Depression , 2006, Journal of clinical psychopharmacology.

[92]  M. Furey,et al.  Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. , 2006, Archives of general psychiatry.

[93]  M. Fava,et al.  Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. , 2006, The American journal of psychiatry.

[94]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[95]  J. Culver,et al.  Adjunctive aripiprazole in treatment-resistant bipolar depression. , 2006, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[96]  A. Rush,et al.  Algorithms and Collaborative-care Systems for Depression: Are They Effective and Why? A Systematic Review , 2006, Biological Psychiatry.

[97]  Klaus P. Ebmeier,et al.  Transcranial magnetic stimulation , 2006 .

[98]  A. Rush,et al.  Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. , 2006, The Journal of clinical psychiatry.

[99]  M. Fava,et al.  Current Status of Augmentation and Combination Treatments for Major Depressive Disorder: A Literature Review and a Proposal for a Novel Approach to Improve Practice , 2006, Psychotherapy and Psychosomatics.

[100]  M. Gitlin Treatment-resistant bipolar disorder , 2006, Molecular Psychiatry.

[101]  J. Calabrese,et al.  Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. , 2006, The American journal of psychiatry.

[102]  P. Mitchell,et al.  A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. , 2005, Journal of affective disorders.

[103]  Thomas E Schlaepfer,et al.  Deep brain stimulation for treatment of refractory depression , 2005, The Lancet.

[104]  R. Shelton,et al.  Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. , 2005, The Journal of clinical psychiatry.

[105]  J. Galea,et al.  Lamotrigine Augmentation Strategy for Patients with Treatment-Resistant Depression , 2005, CNS Spectrums.

[106]  A. Rush,et al.  Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. , 2005, The Journal of clinical psychiatry.

[107]  Barry R. Rittberg,et al.  A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression , 2005, Biological Psychiatry.

[108]  Barry R. Rittberg,et al.  Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study , 2005, Biological Psychiatry.

[109]  Mustafa M. Husain,et al.  Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial , 2005, Biological Psychiatry.

[110]  G. MacQueen,et al.  One‐year outcome with antidepressant – treatment of bipolar depression , 2005, Acta psychiatrica Scandinavica.

[111]  J. Calabrese,et al.  A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. , 2005, The American journal of psychiatry.

[112]  M. Fava,et al.  Ropinirole in Treatment-Resistant Depression: A 16-Week Pilot Study , 2005, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[113]  A. Heinz,et al.  Is dose escalation of antidepressants a rational strategy after a medium–dose treatment has failed? , 2005, European Archives of Psychiatry and Clinical Neuroscience.

[114]  A. Lozano,et al.  Deep Brain Stimulation for Treatment-Resistant Depression , 2005, Neuron.

[115]  M. Fava,et al.  A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. , 2005, The Journal of clinical psychiatry.

[116]  Gin S Malhi,et al.  Bipolar depression: phenomenological overview and clinical characteristics. , 2004, Bipolar disorders.

[117]  B Müller-Oerlinghausen,et al.  The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry , 2004, Pharmacopsychiatry.

[118]  C. Epstein,et al.  Brain Blood‐flow Alterations Induced by Therapeutic Vagus Nerve Stimulation in Partial Epilepsy: II. Prolonged Effects at High and Low Levels of Stimulation , 2004, Epilepsia.

[119]  Alexander L. Miller,et al.  Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. , 2004, Archives of general psychiatry.

[120]  L. San,et al.  Reboxetine adjunct for partial or nonresponders to antidepressant treatment. , 2004, Journal of affective disorders.

[121]  M. Fava,et al.  Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. , 2004, Psychosomatics.

[122]  E. Paykel,et al.  Longitudinal syndromal and sub-syndromal symptoms after severe depression: 10-year follow-up study , 2004, British Journal of Psychiatry.

[123]  S. Pridmore,et al.  Medication Options in the Treatment of Treatment-Resistant Depression , 2004, The Australian and New Zealand journal of psychiatry.

[124]  K. Burdick,et al.  Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. , 2004, The American journal of psychiatry.

[125]  R. Lam,et al.  Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. , 2004, The Journal of clinical psychiatry.

[126]  A. Anand,et al.  Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. , 2004, The Journal of clinical psychiatry.

[127]  H. Möller,et al.  Algorithms for optimizing the treatment of depression: making the right decision at the right time. , 2003, Pharmacopsychiatry.

[128]  J. Calabrese,et al.  Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. , 2003, Archives of general psychiatry.

[129]  L. San,et al.  Tratamiento de combinación con reboxetina en pacientes con depresión mayor no respondedores o con respuesta parcial a inhibidores selectivos de la recaptación de serotonina , 2003 .

[130]  C. Mazure,et al.  Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study , 2003, Biological Psychiatry.

[131]  A. Nierenberg Predictors of response to antidepressants general principles and clinical implications. , 2003, The Psychiatric clinics of North America.

[132]  D. Kupfer,et al.  Is treatment-resistant depression a unique subtype of depression? , 2003, Biological Psychiatry.

[133]  K. Krishnan,et al.  Comorbidity and depression treatment , 2003, Biological Psychiatry.

[134]  Maurizio Fava,et al.  Diagnosis and definition of treatment-resistant depression , 2003, Biological Psychiatry.

[135]  M. Berk,et al.  A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. , 2003, The Journal of clinical psychiatry.

[136]  J. Calabrese,et al.  Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. , 2003, Bipolar disorders.

[137]  John R. Geddes,et al.  Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis , 2003, The Lancet.

[138]  P. Dannon,et al.  A randomized controlled comparison of electroconvulsive therapy and repetitive transcranial magnetic stimulation in severe and resistant nonpsychotic major depression , 2003, Biological Psychiatry.

[139]  M. Fava,et al.  Lithium Augmentation of Nortriptyline for Subjects Resistant to Multiple Antidepressants , 2003, Journal of clinical psychopharmacology.

[140]  A. Rush,et al.  The impact of treatment-resistant depression on health care utilization and costs. , 2002, The Journal of clinical psychiatry.

[141]  P. Houck,et al.  Pramipexole in treatment-resistant depression: a 16-week naturalistic study. , 2002, Bipolar disorders.

[142]  A. Berghöfer,et al.  Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. , 2002, The Journal of clinical psychiatry.

[143]  T. B. Üstün,et al.  Global burden of depressive disorders: The issue of duration , 2002, British Journal of Psychiatry.

[144]  James G Barbee,et al.  Lamotrigine as an augmentation agent in treatment-resistant depression. , 2002, The Journal of clinical psychiatry.

[145]  M. Fava,et al.  Double-Blind Study of High-Dose Fluoxetine Versus Lithium or Desipramine Augmentation of Fluoxetine in Partial Responders and Nonresponders to Fluoxetine , 2002, Journal of clinical psychopharmacology.

[146]  C. Pearlman Electroconvulsive therapy in clinical psychopharmacology. , 2002, Journal of clinical psychopharmacology.

[147]  A. Flint Treatment‐resistant Depression , 2002 .

[148]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold Depressions , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[149]  S. Qvitzau,et al.  Treatment strategies in patients with major depression not responding to first-line sertraline treatment , 2002, Psychopharmacology.

[150]  M. Thase,et al.  Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. , 2002, Archives of general psychiatry.

[151]  H. Sackeim,et al.  Neuropsychiatric applications of transcranial magnetic stimulation: a meta analysis. , 2002, The international journal of neuropsychopharmacology.

[152]  L. Price,et al.  A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine , 2002, Biological Psychiatry.

[153]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and Continuation Treatment of Major Depressive Disorder , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[154]  Cole A. Giller,et al.  Vagus Nerve Stimulation (VNS™) for Treatment-Resistant Depression: Efficacy, Side Effects, and Predictors of Outcome , 2001, Neuropsychopharmacology.

[155]  O. Arthurs,et al.  Transcranial magnetic stimulation for depression and other psychiatric disorders , 2001, Psychological Medicine.

[156]  B. Appelberg,et al.  Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study. , 2001, The Journal of clinical psychiatry.

[157]  M. Fava,et al.  Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. , 2001, The Journal of clinical psychiatry.

[158]  H. Sackeim,et al.  ECT in bipolar and unipolar depression: differences in speed of response. , 2001, Bipolar disorders.

[159]  S H Lisanby,et al.  Magnetic seizure therapy of major depression. , 2001, Archives of general psychiatry.

[160]  S. Kornstein,et al.  Clinical features of treatment-resistant depression. , 2001, The Journal of clinical psychiatry.

[161]  J. Greden The burden of disease for treatment-resistant depression. , 2001, The Journal of clinical psychiatry.

[162]  A. Puech,et al.  Benefits from mianserin augmentation of fluoxetine in patients with major depression non‐responders to fluoxetine alone , 2001, Acta psychiatrica Scandinavica.

[163]  Takeshi Inoue,et al.  Preliminary communication Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression , 2000 .

[164]  Ziad Nahas,et al.  A controlled trial of daily left prefrontal cortex TMS for treating depression , 2000, Biological Psychiatry.

[165]  J. Calabrese,et al.  Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. , 2000, The American journal of psychiatry.

[166]  J. Teasdale,et al.  Effects of cognitive therapy on psychological symptoms and social functioning in residual depression , 2000, British Journal of Psychiatry.

[167]  M. Fava,et al.  Pramipexole Augmentation in the Treatment of Unipolar and Bipolar Depression: A Retrospective Chart Review , 2000, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[168]  J. Kelly,et al.  Effects of reboxetine and sertraline treatments alone and in combination on the binding properties of cortical NMDA and β1-adrenergic receptors in an animal model of depression , 2000, European Neuropsychopharmacology.

[169]  E. Vieta,et al.  Clinical factors associated with treatment noncompliance in euthymic bipolar patients. , 2000, The Journal of clinical psychiatry.

[170]  M. Fava,et al.  Strategies for Managing Depression Refractory to Selective Serotonin Reuptake Inhibitor Treatment: A Survey of Clinicians , 2000, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[171]  A. Serretti,et al.  Effect of reboxetine augmentation in SSRI resistant patients , 2000, Human psychopharmacology.

[172]  Meera Narasimhan,et al.  A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression , 2000, Biological Psychiatry.

[173]  Robert Goodman,et al.  Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study∗ ∗ See accompanying Editorial, in this issue. , 2000, Biological Psychiatry.

[174]  S. Shergill,et al.  Outcome in refractory depression. , 1999, Journal of affective disorders.

[175]  P. Boyer,et al.  Venlafaxine and paroxetine in treatment-resistant depression , 1999, British Journal of Psychiatry.

[176]  D. Puigdemont,et al.  A double-blind, randomized, placebo-controlled trial of Pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors , 1999 .

[177]  L. Price,et al.  Mirtazapine Augmentation in the Treatment of Refractory Depression , 1999 .

[178]  J. Amsterdam,et al.  Treatment resistant depression: methodological overview and operational criteria , 1999, European Neuropsychopharmacology.

[179]  T L Faber,et al.  Brain Blood Flow Alterations Induced by Therapeutic Vagus Nerve Stimulation in Partial Epilepsy: I. Acute Effects at High and Low Levels of Stimulation , 1998, Epilepsia.

[180]  A. Lewy,et al.  Melatonin treatment of winter depression: a pilot study , 1998, Psychiatry Research.

[181]  N. Michael,et al.  Electroconvulsive therapy vs. paroxetine in treatment‐resistant depression — a randomized study , 1997, Acta psychiatrica Scandinavica.

[182]  A. Gelenberg,et al.  Pindolol augmentation of treatment-resistant depressed patients. , 1997, The Journal of clinical psychiatry.

[183]  V. Pérez,et al.  Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment , 1997, The Lancet.

[184]  M. Wolfersdorf,et al.  Combination Therapy Using Moclobemide with Tricyclic and Tetracyclic Antidepressants to Treat Therapy-resistant Depression , 1997, Pharmacopsychiatry.

[185]  A. Rush,et al.  When at first you don't succeed: sequential strategies for antidepressant nonresponders. , 1997, The Journal of clinical psychiatry.

[186]  S. Shergill,et al.  Pharmacological choices after one antidepressant fails: a survey of UK psychiatrists. , 1997, Journal of affective disorders.

[187]  M. Maes,et al.  Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. , 1996, Journal of affective disorders.

[188]  D. O'Leary,et al.  Seven Year Prognosis in Depression , 1996, British Journal of Psychiatry.

[189]  W. Coryell,et al.  Recovery after 5 years of unremitting major depressive disorder. , 1996, Archives of general psychiatry.

[190]  C. Hawley,et al.  Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients , 1996, International clinical psychopharmacology.

[191]  C. Naylor,et al.  Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. , 1996, Archives of general psychiatry.

[192]  P. Baumann,et al.  A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. , 1996, Journal of clinical psychopharmacology.

[193]  Takeshi Inoue,et al.  Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression , 1996, Biological Psychiatry.

[194]  G. Sachs Treatment-resistant bipolar depression. , 1996, The Psychiatric clinics of North America.

[195]  M. Fava,et al.  Definition and epidemiology of treatment-resistant depression. , 1996, The Psychiatric clinics of North America.

[196]  R Ramana,et al.  Residual symptoms after partial remission: an important outcome in depression , 1995, Psychological Medicine.

[197]  Mark Hallett,et al.  Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression , 1995, Neuroreport.

[198]  H. Ortega-Soto,et al.  A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. , 1995, Journal of affective disorders.

[199]  J. Amsterdam,et al.  Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. , 1994, The American journal of psychiatry.

[200]  G. Stein,et al.  Lithium Augmentation Therapy in Tricyclic-Resistant Depression , 1993, British Journal of Psychiatry.

[201]  J. Nobrega,et al.  Desipramine reduces plasma but not brain thyroxine levels , 1993, Biological Psychiatry.

[202]  J. Amsterdam,et al.  Treatment-resistant depression: definition and treatment approaches. , 1990, The Journal of clinical psychiatry.

[203]  World federation of societies of biological psychiatry , 1990, Biological Psychiatry.

[204]  P. Poole‐Wilson,et al.  Double-Blind, Randomised, Cross-Over Comparison of Oral Captopril and Enoximone Added to Diuretic Treatment in Patients with Severe Heart Failure , 1988, Journal of cardiovascular pharmacology.

[205]  J. Davidson,et al.  A comparison of electroconvulsive therapy and combined phenelzine-amitriptyline in refractory depression. , 1978, Archives of general psychiatry.

[206]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[207]  松永 美希 Psychosocial functioning in patients with treatment-resistant depression after group cognitive behavioral therapy , 2010 .

[208]  M. Fava,et al.  Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. , 2009, Drug and alcohol dependence.

[209]  C. Nemeroff,et al.  A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. , 2009, Journal of psychiatric research.

[210]  H. Möller,et al.  Diretrizes da World Federation of Societies of Biological Psychiatry (WFSBP) Part 1: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part I: Acute and continuation treatment of major depressive disorder , 2009 .

[211]  M Velasco,et al.  Neuromodulation of the inferior thalamic peduncle for major depression and obsessive compulsive disorder. , 2007, Acta neurochirurgica. Supplement.

[212]  C. Nemeroff,et al.  Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation , 2007, Neuropsychopharmacology.

[213]  J. Soares,et al.  [Treatment-resistant mood disorders]. , 2007, Revista brasileira de psiquiatria.

[214]  D. Kupfer,et al.  Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. , 2006, The American journal of psychiatry.

[215]  D. Luckenbaugh,et al.  A double-blind, placebo-controlled study of memantine in the treatment of major depression. , 2006, The American journal of psychiatry.

[216]  M. Fava,et al.  The combination of duloxetine and bupropion for treatment‐resistant major depressive disorder , 2006, Depression and anxiety.

[217]  B. Lebowitz,et al.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. , 2006, The American journal of psychiatry.

[218]  M. Case,et al.  A randomized, double‐blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment‐resistant depression , 2006, Depression and anxiety.

[219]  M. Keller,et al.  Issues in treatment-resistant depression. , 2005, The Journal of clinical psychiatry.

[220]  R. Baldessarini,et al.  Antidepressant treatment in bipolar versus unipolar depression. , 2004, The American journal of psychiatry.

[221]  L. San,et al.  [Combination therapy with reboxetine for major depression patients who are partial or nonresponders to serotonin selective reuptake inhibitors]. , 2003, Actas espanolas de psiquiatria.

[222]  R. Joffe Treating mood disorders. , 2003, Journal of psychiatry & neuroscience : JPN.

[223]  L. Price,et al.  A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. , 2002, Biological psychiatry.

[224]  Wei Zhang,et al.  A novel augmentation strategy for treating resistant major depression. , 2001, The American journal of psychiatry.

[225]  J. Mendlewicz,et al.  Treatment-resistant mood disorders: The characterization and definition of treatment-resistant mood disorders , 2001 .

[226]  T. Ohmori,et al.  Open pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression. , 1999, Journal of affective disorders.

[227]  J. Amsterdam,et al.  Clomipramine augmentation in treatment‐resistant depression , 1997, Depression and anxiety.

[228]  R. Joffe,et al.  Combined SSRI-moclobemide treatment of psychiatric illness. , 1994, The Journal of clinical psychiatry.

[229]  A. Nierenberg,et al.  What next? A review of pharmacologic strategies for treatment resistant depression. , 1990, Psychopharmacology bulletin.

[230]  Amsterdam,et al.  Treatment-resistant depression : definition and treatment approaches. Discussion , 1990 .